Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

ABSTRACT: Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

PROVIDER: PRJNA473145 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells

| PRJNA438483 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

| PRJNA438485 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

| PRJNA438486 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

Project description:To obtain differentially expressed genes associated with cetuximab resistance mechanism, we analyzed RNA samples using whole genome microarray expression profiling as a discovery platform to identify genes. Two kinds of RNA samples were extracted from SAS, Sa3, and HSC-3 cells: control cells and cetuximab-resistant cells.

2018-12-01 | GSE114928 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

Project description:To obtain differentially expressed genes associated with cetuximab induced cytotoxicity we analyzed RNA samples using whole genome microarray expression profiling as a discovery platform to identify genes . Two kinds of RNA samples were extracted from HaCaT and HEK 293 cell; without cetuximab and incubation for 24 hours with 1.63μM (fixed maintenance dose) cetuximab.

2018-09-30 | GSE111885 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

2018-09-30 | GSE111886 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-09-30 | GSE111887 | GEO

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Project description:HCC827 cells were grown in gradually increasing concentrations of cetuximab beginning at 0.1 ug/ml. Drug concentrations were slowly increased until the resistant cells were able to proliferate in 100 ug/ml of cetuximab. Individual clones of cetuximab resistant (CR; CR1 to CR4) cells were isolated and confirmed to be drug resistant. Number of samples: 5. Parental HCC827 as a control. 4 Cetuximab resistant clones

2011-11-23 | E-GEOD-30255 | biostudies-arrayexpress

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

2011-11-23 | GSE30255 | GEO

Global gene expression analysis between cetuximab-sensitive and cetuximab-resistant colorectal cancer cells

Project description:Cetuximab is an epidermal growth factor receptor (EGFR)-blocking antibody approved for treatment of metastatic colorectal cancer. We examined differences in global gene expression between the syngeneic DiFi colorectal cancer cells, and a subline of DiFi cells with acquired resistance to cetuximab (DiFi5). We used Affymetrix HG-U133A array to compare the expression pattern of genes that are up-regulated or down-regulated between the parental DiFi colorectal cancer cells and the cetuximab-resistant DiFi5 cells. We generated a cetuximab-resistant DiFi subline, termed DiFi5, by chronic exposure of parental DiFi cells to serially increased doses of cetuximab (from 0.5 nM to 5 nM) for over 1 year. The resulting DiFi5 subline exhibits significant resistance to cetuximab-induced apoptosis. After we confirmed that the phenotype was stable over a period of time of more than 6 months, the RNA from DiFi and DiFi5 cells were extracted and hybridized to an Affymetrix HG-U133A array according to the manufacturerâs instructions. Following the hybridization, the array was scanned using a laser confocal scanner, and microarray image data were analyzed using DNA-Chip Analyzer (dChip), version 1.3, by the Sequencing and Microarray Facility at MD Anderson Cancer Center.

2016-07-17 | E-GEOD-71210 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data